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Abstract
Background: We aimed to determine whether early statin use following recanalization therapy improves the
functional outcome of ischemic stroke.
Methods: Using a prospective stroke registry database, we identified a consecutive 337 patients within 6 h of onset
who had symptomatic stenosis or occlusion of major cerebral arteries and received recanalization therapy. Based on
commencement of statin therapy, patients were categorized into administration on the first (D1, 13.4 %), second
(D2, 20.8 %) and third day or later (D ≥ 3, 15.4 %) after recanalization therapy, and no use (NU, 50.4 %). The primary
efficacy outcome was a 3-month modified Rankin Scale score of 0–1, and the secondary outcomes were neurologic
improvement, neurologic deterioration and symptomatic hemorrhagic transformation during hospitalization.
Results: Earlier use of statin was associated with a better primary outcome in a dose-response relationship (P for
trend = 0.01) independent of premorbid statin use, stroke history, atrial fibrillation, stroke subtype, calendar year, and
methods of recanalization therapy. The odds of a better primary outcome increased in D1 compared to NU
(adjusted odds ratio, 2.96; 95 % confidence interval, 1.19–7.37). Earlier statin use was significantly associated with less
neurologic deterioration and symptomatic hemorrhagic transformation in bivariate analyses but not in multivariable
analyses. Interaction analysis revealed that the effect of early statin use was not altered by stroke subtype and
recanalization modality (P for interaction = 0.97 and 0.26, respectively).
Conclusion: Early statin use after recanalization therapy in ischemic stroke may improve the likelihood of a
better functional outcome without increasing the risk of intracranial hemorrhage.
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Background
Recanalization therapy for acute ischemic stroke aims to
restore the patency of occluded cerebral arteries and
subsequent brain reperfusion [1]. Since the introduction
of intravenous (IV) thrombolysis, additional attempts
have been made with a new generation of thrombectomy
devices that show much higher successful recanalization
rates [2, 3].
Unfortunately, this improvement is in discord with
clinical outcome; only ~ 30–40 % of ischemic stroke
patients had good functional outcome irrespective of
treatment modality [2–4]. The discrepancy between re-
canalization and functional outcome may be attributed,
at least in part, to no-reflow phenomenon, reperfusion
injury, and re-occlusion [4, 5]. A number of studies have
been designed to improve outcome by preventing these
adverse events [6, 7]. Most recently, early aspirin use
after IV thrombolysis was investigated for the prevention
of secondary thrombosis [8]. It did not improve outcome
but increased bleeding.
Pleiotropic effects of statin might be beneficial for
improving functional outcome and preventing intracra-
nial hemorrhage in patients who have undergone recan-
alization therapy [9, 10]. In experimental stroke models,
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early statin administration enhances thrombolysis, aug-
ments antithrombotic responses, increases cerebral
blood flow, and decreases matrix metalloproteinase-9
(MMP-9) levels [11–14]. These actions predispose the
prevention of re-occlusion and improve the prospects
for brain perfusion. Until now, the effect of statin treat-
ment following recanalization therapies has been exam-
ined once in patients who have received IV thrombolysis
[15]. The effects of statin may be maximized in patients
who present with acute steno-occlusion of the major
cerebral arteries and are treated successfully with recan-
alization therapy, including endovascular approaches.
Therefore, we aimed to determine whether early statin
use in patients with acute symptomatic steno-occlusion
of major cerebral arteries who are treated with recanali-
zation therapy is associated with a better 3-month func-
tional outcome irrespective of recanalization modality.
Associations of early statin use were further analyzed in
relation to the following other neurologic outcomes ob-
tained during hospitalization: stroke recurrence, neurologic
improvement, neurologic deterioration, and symptomatic
hemorrhagic transformation. Furthermore, we studied the
effect of statin dose and the heterogeneity of the early sta-
tin effect by stroke subtype and recanalization modality.
Methods
Institutional review board approval and patient consent
This study was approved by the Seoul National University
Bundang Hospital Istitutional Review Board (SNUBH IRB)
with waiver of informed consent because of its minimal
risk and retrospective nature.
Study participants
Based on a prospective stroke registry database [16], a con-
secutive series of patients 1) who were admitted to Seoul
National University Bundang Hospital for acute ischemic
stroke within 6 h of symptom onset between March 2004
and September 2011, 2) who underwent recanalization
therapy and 3) who had symptomatic stenosis (>50 %) or
occlusion of a major cerebral artery at initial angiographic
evaluation were identified. According to the institutional
stroke image protocols, patients who were potentially
eligible for recanalization therapy underwent computed
tomographic angiography (CTA) or magnetic resonance
angiography (MRA) at presentation. In this study, the cere-
bral arteries of interest were the internal carotid artery
(ICA), middle cerebral artery (MCA), anterior cerebral ar-
tery (ACA), posterior cerebral artery (PCA), basilar artery
(BA), and vertebral artery (VA). Patients without a 3-month
modified Rankin Scale (mRS) score were excluded.
Data collection and outcome measures
Review of electronic medical records and the registry
database provided clinical information on demographic
factors, baseline stroke severity as measured by the
National Institute of Heath Stroke Scale (NIHSS),
vascular risk factors, and acute stroke management.
Recanalization modalities were classified into the fol-
lowing types: IV thrombolysis (IV-only), intra-arterial
treatment (IA-only), and combination of IV and IA
treatments. IA treatment included IA use of chemical
thrombolytic agents, clot maceration by multiple pas-
sages of microcatheter/microwire [17], and mechanical
thrombectomy using devices such as the Penumbra sys-
tem and the Solitaire. Stroke subtype was assigned by a
vascular neurologist according to the Trial of Org 10172
in Acute Stroke Treatment (TOAST) [18] criteria
and validated at a weekly stroke registry meeting by
consensus.
Premorbid statin use, defined as receiving statin ther-
apy within 1 week before stroke onset, was ascertained
by patient or proxy interview. Timing of statin adminis-
tration after recanalization therapy, specific statin type,
and initial dose were ascertained by review of the elec-
tronic medical records. Commencement of statin ther-
apy was categorized according to the following scheme:
statin administration on the first (D1), second (D2), and
third day or later (D ≥ 3) of hospitalization, and no statin
therapy (NU). Since statin was used in several forms and
doses, we substituted a specific dose of a specific form
of statin with an equivalent dose of atorvastatin (10 mg
or less, 20 mg, 40 mg and 80 mg) [19, 20]. The atorva-
statin equivalent doses were then categorized into no
use, low (less than atorvastatin equivalent dose of
40 mg) and high dose (40 mg or more) [21].
After IRB approval, we prospectively collected NIHSS
scores at baseline and on the second and seventh day of
hospitalization or at discharge, as well as the 3-month
mRS scores, as part of an institutional quality-of-care
monitoring program for hospitalized stroke patients.
The primary efficacy outcome of the study was good
functional outcome at 3 months (mRS score of 0–1)
[22]. A favorable outcome, defined as a 3-month mRS
score of 0–2, was a secondary outcome.
Other secondary outcomes included neurologic im-
provement, neurologic deterioration, and ischemic
stroke recurrence during hospitalization. Neurologic
improvement was defined as a reduction in total
NIHSS score of ≥4 points from baseline to discharge or a
NIHSS score of 0–1 at discharge. Neurologic deterior-
ation was defined as an increase in a total NIHSS score
of 4 or more points from baseline [23]. Ischemic stroke
recurrence was defined as a significant change in neuro-
logic symptoms and signs accompanied by corresponding
new discrete lesions on diffusion-weighted magnetic res-
onance images. Symptomatic hemorrhagic transform-
ation was included as a safety outcome and was defined
as a local or remote parenchymal hemorrhage type 2 on
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a post-treatment brain image combined with an increase
of 4 points or more in the NIHSS score from baseline or
with the occurrence of death [24].
Statistical analysis
Study variables are expressed as mean ± SD, median
(interquartile range, IQR), or number of patients
(percentage) according to variable characteristics. Statin
therapy was characterized according to the commence-
ment of statin therapy, type, and dose (Additional file 1:
Figure S1, S2 and Table S1). Baseline characteristics
were compared according to the statin starting time
using the Pearson χ2 test, ANOVA, and Kruskal-Wallis
test when appropriate (Table 1).
Dose-response relationships between the statin start-
ing time and the primary and secondary outcomes were
evaluated using the Mantel-Haenszel test for trend
(Table 2). Regarding multivariable analysis, adjusted
odds ratios (ORs) of the statin starting time (D1, D2 and
D ≥ 3) compared to NU were estimated for various out-
comes, and dose-response relationships were character-
ized by likelihood ratio tests for trend (Fig. 1). In cases
where the event number of D2 or D ≥ 3 was less than 5,
the statin starting time was re-categorized into three
groups: D1, D ≥ 2 and NU.
Variables for adjustment were selected based on their
p values (<0.2) and biological plausibility. To mitigate
unmeasured confounding by recent advances in stroke
care, calendar year was included in multivariable models
(Additional file 1: Table S2). Because the number of
patients with symptomatic hemorrhagic transformation
was not enough to adjust all potential confounders at
once, multivariable analyses were carried out using vari-
ous sets of confounders as post-hoc analyses (Additional
file 1: Table S3).
To investigate the heterogeneity of the early statin
effect according to stroke subtype and recanalization
modality, we performed subgroup analyses (cardioem-
bolic vs. non-cardioembolic stroke and IV-only vs.
IA-only vs. combined treatment) (Table 3 and 4).
The statistical significance of the interaction between
the statin starting time and stroke subtype or recana-
lization modality was examined in multivariable models.
Finally, the associations of the statin dose with 3-month
mRS 0–1 and symptomatic hemorrhagic transformation
were analyzed (Additional file 1: Table S4 and S5). All
statistical analyses were performed with SPSS version
18.0 (SPSS Inc., Chicago, IL). A two-sided p value of 0.05
was generally considered a minimum level of statistical
significance.
Table 1 Comparison of baseline characteristics according to the statin starting time
Variables Statin use No use P value*
D1 D2 D ≥ 3
(N = 45) (N = 70) (N = 52) (N = 170)
Age, years, mean ± SD 67.6 ± 11.6 69.5 ± 12.0 68.0 ± 12.5 69.6 ± 12.7 0.69
Male sex 30 (66.7 %) 36 (51.4 %) 31 (59.6 %) 91 (53.5 %) 0.34
Time from onset to arrival, hours, mean ± SD 1.4 ± 1.3 1.6 ± 1.3 s 1.6 ± 1.4 1.5 ± 1.2 0.66
History of stroke 12 (26.7 %) 12 (17.1 %) 6 (11.5 %) 46 (27.1 %) 0.07
Hypertension 28 (62.2 %) 42 (60.0 %) 32 (61.5 %) 95 (55.9 %) 0.80
Diabetes mellitus 10 (22.2 %) 13 (18.6 %) 9 (17.3 %) 30 (17.6 %) 0.91
Atrial fibrillation 15 (33.3 %) 37 (52.9 %) 12 (23.1 %) 54 (31.8 %) 0.003
Premorbid statin use 8 (17.8 %) 10 (14.3 %) 6 (11.5 %) 15 (8.8 %) 0.33
Baseline NIHSS score, median (IQR) 15 (7–18) 11 (6-20) 12 (7.5–17) 15 (9–20) 0.14
Stroke subtype 0.002
LAA 20 (44.4 %) 27 (38.6 %) 21 (40.4 %) 42 (24.7 %)
CE 13 (28.9 %) 39 (55.7 %) 22 (42.3 %) 96 (56.5 %)
UD or OD 12 (26.7 %) 4 (5.7 %) 9 (17.3 %) 32 (18.8 %)
Recanalization modality 0.007
IV-only 15 (33.3 %) 28 (40.0 %) 13 (25.0 %) 30 (17.6 %)
IA-only 15 (33.3 %) 15 (21.4 %) 20 (38.5 %) 55 (32.4 %)
Combined treatment 15 (33.3 %) 27 (38.6 %) 19 (36.5 %) 85 (50.0 %)
Values represent number of patients (percentage) if not indicated
*P values were obtained by Pearson χ2 test, ANOVA test, and Kruskal-Wallis test according to characteristics of variables
LAA is the abbreviation for large artery atherosclerosis; CE for cardioembolism, UD or OD for undetermined or other determined, IV-only for intravenous thrombolysis-only,
IA-only for intra-arterial treatment-only, and IQR for interquartile range
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Results
Among 501 patients with acute ischemic stroke who
were hospitalized within 6 h of onset and who under-
went recanalization therapy, 345 had symptomatic sten-
osis or occlusion of major cerebral arteries at initial
angiographic evaluation. Of those, eight patients were
excluded due to no 3-month mRS, leaving a total of
337 patients included in the study. Mean age was
69.1 ± 12.4 years, with men comprising 55.8 %. Median
baseline NIHSS score was 13 (IQR, 7–19). Recanalization
therapy was IV-only in 25.5 %, IA-only in 31.2 %, and
combined treatment in 43.3 %.
One-hundred sixty seven patients (49.6 %) received
statin therapy during hospitalization. Analysis of the
secular trends of the statin starting time demonstrated a
gradual increase in the proportion of early users over
time (Additional file 1: Figure S1). The proportion of pa-
tients receiving a statin at D1 was 0 % in 2004, but in-
creased to 35 % in 2010. In total, 45 patients (13.4 %)
started statin therapy at D1, 70 (20.8 %) started at D2,
and 52 (15.4 %) started at D ≥ 3, while 170 (50.4 %) pa-
tients did not receive statin during hospitalization. Com-
parison of baseline characteristics revealed that atrial
fibrillation, stroke subtype and recanalization modality
were associated with the statin starting time (Table 1).
With respect to the statin dose, 58.1 % of the statin users
received a high dose of statin (40 mg or more of atorva-
statin equivalent dose) (Additional file 1: Table S1); the
proportion of high dose users began to increase in 2007
and leaped in 2009 (Additional file 1: Figure S2).
Comparisons between statin users vs. none users dem-
onstrated better primary outcome (3-month mRS 0–1)
in statin users (37.7 %) than in none users (22.4 %). Earl-
ier use was positively associated with a better primary
outcome (P for trend = 0.002) (Table 2). A similar
trend was observed with respect to favorable outcome
(mRS 0–2) (P for trend = 0.004). Earlier use was also
associated with neurologic deterioration and symptom-
atic hemorrhagic transformation but not with neurologic
improvement and ischemic recurrence (Table 2).
The dose-response relationship between the statin
starting time and better primary outcome remained sig-
nificant after adjustment for baseline NIHSS score,
premorbid statin use, recanalization modality, atrial fib-
rillation, stroke subtype, calendar year, and stroke history
(P for trend = 0.01). The odds of better primary outcome
independently increased about 3-fold by commence-
ment of statin therapy at D1 compared with no use
(Additional file 1: Figure S1 and Table S2). Among the
secondary outcomes, a dose-response relationship with
the statin starting time was observed for favorable out-
come and neurologic deterioration but not for neurologic
improvement in multivariable analysis. With respect
to symptomatic hemorrhagic transformation, all the
multivariable analyses showed significant reduction of
its odds in starting statin therapy at D ≥ 2 but not at D1
compared with no use (Additional file 1: Table S3).
Subgroup analysis according to stroke subtype re-
vealed dose-response relationships between the statin
starting time and better primary and more favorable out-
comes in patients with non-cardioembolic stroke, and
between the statin starting time and symptomatic
hemorrhagic transformation in patients with cardioem-
bolic stroke (Table 3). Interaction analysis with adjust-
ments for potential confounders did not show any
statistically significant heterogeneity of the early statin
effect between cardioembolic and non-cardioembolic
stroke (P for interaction = 0.97).
Subgroup analysis according to recanalization modality
demonstrated a clear dose-response relationship between
Table 2 Comparison of clinical outcomes according to the statin starting time
Statin use No use P trend*
D1 D2 D ≥ 3 (N = 170)
(N = 45) (N = 70) (N = 52)
3-Month functional outcome
Better primary outcome (mRS, 0-1) 19 (42.2 %) 26 (37.1 %) 18 (34.6 %) 38 (22.4 %) 0.002
Favorable outcome (mRS, 0-2) 26 (57.8 %) 30 (42.9 %) 29 (55.8 %) 57 (33.5 %) 0.004
Neurologic outcome during hospitalization
Neurologic improvementa 24 (53.3 %) 39 (55.7 %) 38 (73.1 %) 84 (49.4 %) 0.87
Neurologic deteriorationb 7 (15.6 %) 10 (14.3 %) 1 (1.9 %) 45 (26.5 %) 0.02
Ischemic recurrence 8 (17.8 %) 11 (15.7 %) 4 (7.7 %) 27 (15.9 %) 0.84
Symptomatic hemorrhagic transformationc 1 (2.2 %) 2 (2.9 %) 0 (0.0 %) 17 (10.0 %) 0.01
See footnotes of Table 1 for definitions and abbreviations
Values represent number of patients (percentage)
*P values were obtained by Mantel-Haenszel test for trend
aNeurologic improvement was defined as a decrease of ≥ 4 NIHSS score or a NIHSS score of 0 or 1 at discharge
bNeurologic deterioration was defined as an increase of ≥ 4 NIHSS score
cThe definition of symptomatic hemorrhagic transformation was adopted from the SITS-MOST study [24]
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the statin starting time and better primary/more favorable
outcome and neurologic deterioration in patients who re-
ceived combined treatment but not in those who received
IV-only or IA-only (Table 4). However, there was no sta-
tistically significant interaction between the statin starting
time and recanalization modality in the multivariable
model (P for interaction = 0.26).
With regard to statin dose, a higher dose tended to in-
crease the odds of better primary outcome compared to
no use (p for trend = 0.07) while significantly reducing
the odds of symptomatic hemorrhagic transformation
(p for trend = 0.03) (Additional file 1: Table S4 and S5).
Discussion
Our study demonstrates that early use of statin may
improve functional outcome in patients with acute
symptomatic steno-occlusion of major cerebral arteries
treated with recanalization therapy. Our findings also
highlight that the use of statin is most effective when
started on the first day after recanalization therapy.
Fig. 1 Adjusted odds ratios of the statin starting time with respect to various clinical outcomes. Statin starting time was defined as starting statin
therapy at D1, D2, D ≥ 3, or no use, or as starting statin therapy at D1, D ≥ 2, and no use when event number of D2 or D ≥ 3 was less than 5. The
adjusted odds ratios (circle) and 95 % confidence intervals (solid line) were estimated using multiple logistic regression models with adjustments
for premorbid statin use, stroke history, atrial fibrillation, calendar year, stroke subtype, baseline NIHSS score, and recanalization modality. *Ps were
calculated by log likelihood test for trend. mRS is the abbreviation for modified Rankin Score
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Furthermore, the effect of statin therapy did not differ
with regard to stroke subtype and recanalization modal-
ity. As for safety, earlier starting or higher dose of statin
therapy did not increase the risk of symptomatic
hemorrhagic transformation but rather decreased this
safety metric.
While the efficacy of early statin use after acute coron-
ary syndrome has been reported [25, 26], the use of sta-
tin in patients with acute ischemic stroke and treated
with recanalization therapy has been investigated on a
limited scale. Recently, the THRombolysis and Statins
(THRaST) study showed that statin use in the acute
phase (within 72 h) after intravenous thrombolysis might
positively influence short- and long-term outcomes by
increasing neurologic improvement (OR, 1.68) and fa-
vorable functional outcome (OR, 1.63), and by reducing
neurologic deterioration (OR, 0.31) and death (OR 0.48)
[15]. However, several potential limitations of this data
should be considered. First, the THRaST study did not
determine dose-response relationships between the sta-
tin starting time and clinical outcomes. Second, 22 % of
the THRaST participants had atrial fibrillation, but the
study did not address the potential efficacy and safety
concerns related to early use of statin in cardioembolic
stroke, a distinct stroke subtype in terms of stroke
mechanism and risk of hemorrhagic transformation.
Lastly, the THRaST study targeted patients treated with
intravenous thrombolysis only, but did not target those
treated with IA-only or combined treatment. The pro-
portion of patients treated by endovascular approaches
is not negligible nowadays. In our study, approximately
75 % of patients who received recanalization therapy
were treated with IA-only or combined treatment.
Our study addressed three points: First, starting statin
at the first day after recanalization therapy increased the
odds of a better functional outcome by approximately
three-fold and this beneficial effect decreased gradually
over time. The proportion of patients who started statin
therapy at the first hospital day was 35 % in 2010 and
21 % in 2011 (Additional file 1: Figure S1) despite the
overt increase of statin users since 2007. Therefore, we
may have a window of opportunity to improve outcome
by commencing statin therapy at this early time-point.
Second, our study showed that early statin therapy did
not increase, and that it rather decreased the risk of
symptomatic hemorrhagic transformation in patients
with cardioembolic stroke; also, the beneficial effect of
early statin therapy was not altered by stroke subtype
(cardioembolic vs. non-cardioembolic). Since early dif-
ferentiation of cardioembolic stroke from other stroke
subtypes may not be feasible in most practices [27], this
study highlights the safety and potential benefit of early
statin use in patients with acute symptomatic steno-
occlusion who are treated with recanalization therapy
and whose stroke mechanisms were obscure at presenta-
tion. Third, with respect to recanalization modality,
Table 3 Subgroup analysis according to stroke subtype (cardioembolic stroke vs. non-cardioembolic stroke)
Outcomes Statin use No Use P trend*
D1 D2 D ≥ 3
Cardioembolic stroke
No. of patients 13 39 22 96
Better primary outcome (mRS, 0-1) 3 (23.1 %) 13 (33.3 %) 7 (31.8 %) 19 (19.8 %) 0.19
Favorable outcome (mRS, 0-2) 4 (30.8 %) 16 (41.0 %) 9 (40.9 %) 32 (33.3 %) 0.63
Neurologic improvement 7 (53.8 %) 22 (56.4 %) 14 (63.6 %) 51 (53.1 %) 0.75
Neurologic deterioration 3 (23.1 %) 4 (10.3 %) 0 (0.0 %) 26 (27.1 %) 0.06
Ischemic recurrence 4 (30.8 %) 4 (10.3 %) 2 (9.1 %) 11 (11.5 %) 0.28
Symptomatic hemorrhagic transformation 0 (0.0 %) 1 (2.6 %) 0 (0.0 %) 10 (10.4 %) 0.04
Non-cardioembolic strokea
No. of patients 32 31 30 74
Better primary outcome (mRS, 0-1) 16 (50.0 %) 13 (41.9 %) 11 (36.7 %) 19 (25.7 %) 0.01
Favorable outcome (mRS, 0-2) 22 (68.8 %) 14 (45.2 %) 20 (66.7 %) 25 (33.8 %) 0.003
Neurologic improvement 17 (53.1 %) 15 (54.8 %) 24 (80.0 %) 40 (54.1 %) 0.86
Neurologic deterioration 4 (12.5 %) 6 (19.4 %) 1 (3.3 %) 19 (25.7 %) 0.13
Ischemic recurrence 4 (12.5 %) 7 (22.6 %) 2 (6.7 %) 16 (21.6 %) 0.42
Symptomatic hemorrhagic transformation 1 (3.1 %) 1 (3.2 %) 0 (0.0 %) 7 (9.5 %) 0.14
See footnotes of Table 1 and 2 for definitions and abbreviations
Values represent number of patients (percentage)
*P values were calculated by Mantel-Haenszel test for trend
aNon-cardioembolism stroke consists of large artery atherosclerosis, stroke of other determined as well as undetermined etiology, according to the TOAST classification [18]
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there was no significant heterogeneity of the early statin
effect, although a clear benefit was observed in the com-
bined treatment group. The relatively small sample size
of this study for subgroup analysis suggests the need of a
study with a larger sample size.
There has been some skepticism regarding the in-
creased risk of symptomatic hemorrhagic transformation
associated with statin therapy after IV and IA thromb-
olysis [28, 29]. The results of THRaST and our study
taken together suggest that early use of statin after
thrombolysis does not increase, and may reduce the risk
of hemorrhagic transformation. Furthermore, our study
demonstrates the dose-response relationship between sta-
tin dose and the prevention of symptomatic hemorrhagic
transformation.
Analysis of short-term clinical outcomes during
hospitalization suggests that early statin therapy might
potentially prevent neurologic deterioration and symp-
tomatic hemorrhagic transformation. These findings
support the hypothesis that statin therapy may protect
neuronal cells from reperfusion injury and major symp-
tomatic brain arteries from re-occlusion [30]. Practically
speaking, the risk of neurologic deterioration is time-
dependent, [31], and starting statin therapy immediately
after or even before recanalization therapy may maximize
the statin effect.
We note several potential study limitations. First, the
study was conducted in a single community-based hos-
pital, and the study participants were identified in a
retrospective manner. Although the patients were en-
rolled from the prospective stroke registry database and
the study outcomes were captured prospectively, we
may be dealing with patients who do not represent the
community-at large, and thus, our findings may not be
representative of other populations. Furthermore, con-
sidering the observational nature of our study design,
residual or unmeasured confounding effects could be in-
troduced and, hence, our results are not free of risk of
Table 4 Comparison of stroke outcomes according to the statin starting time and recanalization modalities
Outcome Statin use No Use P trend*
D1 D2 D ≥ 3
IV-only
No. of patients 15 28 13 30
Better primary outcome (mRS, 0-1) 9 (60.0 %) 9 (32.1 %) 5 (38.5 %) 13 (43.3 %) 0.66
Favorable outcome (mRS, 0-2) 11 (73.3 %) 11 (39.3 %) 7 (53.8 %) 16 (46.7 %) 0.65
Neurologic improvement 8 (53.3 %) 15 (53.6 %) 8 (61.5 %) 13 (43.3 %) 0.95
Neurological deterioration 1 (6.7 %) 6 (21.4 %) 1 (7.7 %) 8 (26. 7 %) 0.20
Ischemic recurrence 2 (13.3 %) 6 (21.4 %) 2 (15.4 %) 4 (13.3 %) 0.71
Symptomatic hemorrhagic transformation 1 (6.7 %) 0 (0.0 %) 0 (0.0 %) 2 (6.7 %) 0.61
IA-only
No. of patients 15 15 20 55
Better primary outcome (mRS, 0-1) 3 (20.0 %) 5 (33.3 %) 5 (25.0 %) 9 (16.4 %) 0.38
Favorable outcome (mRS, 0-2) 4 (26.7 %) 5 (33.3 %) 9 (45.0 %) 16 (29.1 %) 0.96
Neurologic improvement 7 (46.7 %) 7 (46.7 %) 13 (65.0 %) 31 (56.4 %) 0.43
Neurological deterioration 5(33.3 %) 1 (6.7 %) 0 (0.0 %) 15 (27.3 %) 0.66
Ischemic recurrence 3 (20.0 %) 0 (0.0 %) 1 (5.0 %) 10 (18.2 %) 0.49
Symptomatic hemorrhagic transformation 0 (0.0 %) 1 (6.7 %) 0 (0.0 %) 7 (12.7 %) 0.08
Combined treatment
No. of patients 15 27 19 85
Better Primary outcome (mRS, 0-1) 7 (46.7 %) 12 (44.4 %) 8 (42.1 %) 16 (18.8 %) 0.002
Favorable outcome (mRS, 0-2) 11 (73.3 %) 14 (51.9 %) 13 (68.4 %) 25 (29.4 %) <0.001
Neurologic improvement 9 (60.0 %) 17 (63.0 %) 17 (89.5 %) 43 (50.6 %) 0.23
Neurological deterioration 1 (6.7 %) 4 (11.1 %) 0 (0.0 %) 22 (25.9 %) 0.02
Ischemic recurrence 3 (20.0 %) 5 (18.5 %) 1 (5.3 %) 13 (15.3 %) 0.63
Symptomatic hemorrhagic transformation 0 (0.0 %) 1 (3.7 %) 0 (0.0 %) 8 (9.4 %) 0.09
See footnotes of Table 1 and 2 for definitions and abbreviations
Values represent number of patients (percentage)
*P values were calculated by the Mantel-Haenszel test for trend
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inevitable biases despite adjusting for potential con-
founders through modeling. For example, the rate of sta-
tin use increased over time, therefore improvement of
outcome by statin use may be attributed to improvement
of stroke management over time, although calendar year
was included in the multivariable models to adjust for
that kind of confounding effect. Second, subgroups in
our analysis were occasionally small and therefore our
findings based on multiple comparisons could be be-
cause of chance. However, the subgroup analysis accord-
ing to recanalization modality suggested the possibility
of effect modification, although this was statistically not
significant. Residual confounding by recanalization mo-
dality also cannot be excluded. Third, all forms and
doses of statins were converted to atorvastatin equiva-
lents as though there was one type of statin drug and
the statin starting time was not considered in the ana-
lysis of statin dose. The heterogeneity of the early statin
effect according to statin form and dose should be con-
sidered in a study with a larger sample size. Forth, there
were concerns that physician might use statin at earlier
time in patients with successful recanalization and it
would affect the result. Because we did not analyze the
association between successful recanalization and statin
starting time in this study, that problem could not be
solved exactly. However, IA-only and combined treat-
ment groups showed similar or low rates of statin use at
the first day of admission (14.2 % and 10.3 %) compared
with the IV-only group (17.4 %) although higher recana-
lization rates were expected in the former groups, and
these features might mitigate our concerns. Finally, it
should be clearly noted that less frequent symptomatic
hemorrhagic transformation and neurologic deterior-
ation in statin users might be attributed to preferential
underuse of statin in patients with high risk of
hemorrhagic transformation or worse prognosis. A ran-
domized clinical trial would be a more robust setting for
answering the questions we posed.
Conclusion
Early use of statin after recanalization therapy may
improve functional outcome without increasing intracra-
nial hemorrhage in patients with symptomatic steno-
occlusion of major cerebral arteries. The effect was
noted in all stroke subtypes and regardless of recanaliza-
tion modality.
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